CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
Octagamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04411667
NCT04411667Phase 4Completed
CompareCT.gov

Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection

George Sakoulas, MD·interventional·Posted Jun 2, 2020·Updated Jun 25, 2021

In Brief

A Phase 4 clinical trial evaluating Octagam for Sars-CoV2. Completed, enrolled 34 participants across 2 sites.

Detailed Summary

The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSars-CoV2
CountriesUnited States
CollaboratorsOctapharma

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJun 2, 2020
Enrollment StartApr 28, 2020
Primary CompletionJun 23, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.1 years ago

Interventions

Octagamdrug

Standard of Care plus Octagam infusion for 3 days.